BEAR for Women Who Have Experienced Sexual Assault and Have Suicidal Thoughts
Public ClinicalTrials.gov record NCT07902050. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Utilizing the BEAR Therapeutic Group for Women With Interpersonal Violence to Reduce Suicidality and Enhance Self-efficacy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical study is to learn if the BEAR intervention effects outcome in women who have experienced sexual assault (broadly defined) and who have suicidal thinking. The main questions it aims to answer are: * Does this intervention decrease suicidal ideation? * Can this intervention increase self-efficacy in this population? All women will participate in a 12 week therapy group, which is conducted in-person. Participants will * Actively participate in the intervention, which is 1.5 hours, once per week for 12 weeks. * Complete weekly forms prior to group about suicidal thoughts and behaviors * Complete a series of questionnaires at baseline, six weeks, post-group, and at 3- and 12- month follow up. * Complete a qualitative interview about their experience of the intervention at post-group and one year follow up.
Study identification
- NCT ID
- NCT07902050
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 36 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2026 (Estimated)
- Primary completion
- Jan 2029 (Estimated)
- Completion
- Jan 2030 (Estimated)
- Last update posted
- Oct 28, 2026
2026 – 2030
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford University School of Medicine | Palo Alto | California | 94304 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07902050, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 28, 2026 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07902050 live on ClinicalTrials.gov.